[MAYBANK] QoQ Annualized Quarter Result on 30-Sep-2017 [#3]

Announcement Date
30-Nov-2017
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2017
Quarter
30-Sep-2017 [#3]
Profit Trend
QoQ- 6.87%
YoY- 22.96%
View:
Show?
Annualized Quarter Result
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
Revenue 46,048,782 46,061,340 45,580,310 45,059,564 44,400,754 45,112,276 44,657,902 2.07%
PBT 10,332,482 10,226,672 10,098,096 9,562,597 8,987,122 8,996,280 8,844,450 10.95%
Tax -2,543,646 -2,628,720 -2,301,222 -2,168,210 -2,048,460 -2,015,864 -1,880,558 22.37%
NP 7,788,836 7,597,952 7,796,874 7,394,386 6,938,662 6,980,416 6,963,892 7.77%
-
NP to SH 7,660,098 7,484,144 7,520,542 7,184,590 6,722,474 6,811,188 6,742,992 8.89%
-
Tax Rate 24.62% 25.70% 22.79% 22.67% 22.79% 22.41% 21.26% -
Total Cost 38,259,946 38,463,388 37,783,436 37,665,177 37,462,092 38,131,860 37,694,010 1.00%
-
Net Worth 71,853,940 72,802,528 72,420,516 70,446,256 69,268,350 70,457,936 66,810,691 4.98%
Dividend
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
Div 5,460,109 - 5,884,367 3,174,746 4,716,806 - 5,168,567 3.73%
Div Payout % 71.28% - 78.24% 44.19% 70.16% - 76.65% -
Equity
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
Net Worth 71,853,940 72,802,528 72,420,516 70,446,256 69,268,350 70,457,936 66,810,691 4.98%
NOSH 10,945,196 10,906,379 10,782,745 10,352,435 10,253,926 10,178,105 9,939,552 6.65%
Ratio Analysis
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
NP Margin 16.91% 16.50% 17.11% 16.41% 15.63% 15.47% 15.59% -
ROE 10.66% 10.28% 10.38% 10.20% 9.70% 9.67% 10.09% -
Per Share
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
RPS 421.68 424.91 426.03 435.26 433.01 443.23 449.29 -4.15%
EPS 70.40 69.04 72.04 69.40 65.56 66.92 67.84 2.50%
DPS 50.00 0.00 55.00 30.67 46.00 0.00 52.00 -2.58%
NAPS 6.5799 6.716 6.769 6.8048 6.7553 6.9225 6.7217 -1.41%
Adjusted Per Share Value based on latest NOSH - 10,207,482
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
RPS 381.61 381.71 377.73 373.41 367.95 373.85 370.08 2.07%
EPS 63.48 62.02 62.32 59.54 55.71 56.44 55.88 8.89%
DPS 45.25 0.00 48.76 26.31 39.09 0.00 42.83 3.74%
NAPS 5.9546 6.0332 6.0016 5.8379 5.7403 5.8389 5.5367 4.98%
Price Multiplier on Financial Quarter End Date
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
Date 29/06/18 30/03/18 29/12/17 29/09/17 30/06/17 31/03/17 30/12/16 -
Price 9.00 10.60 9.80 9.53 9.63 8.92 8.20 -
P/RPS 2.13 2.49 2.30 2.19 2.22 2.01 1.83 10.68%
P/EPS 12.83 15.35 13.94 13.73 14.69 13.33 12.09 4.05%
EY 7.79 6.51 7.17 7.28 6.81 7.50 8.27 -3.91%
DY 5.56 0.00 5.61 3.22 4.78 0.00 6.34 -8.40%
P/NAPS 1.37 1.58 1.45 1.40 1.43 1.29 1.22 8.06%
Price Multiplier on Announcement Date
30/06/18 31/03/18 31/12/17 30/09/17 30/06/17 31/03/17 31/12/16 CAGR
Date 30/08/18 28/05/18 28/02/18 30/11/17 30/08/17 25/05/17 23/02/17 -
Price 9.96 10.00 10.46 9.21 9.46 9.57 8.38 -
P/RPS 2.36 2.35 2.46 2.12 2.18 2.16 1.87 16.83%
P/EPS 14.20 14.48 14.88 13.27 14.43 14.30 12.35 9.78%
EY 7.04 6.90 6.72 7.54 6.93 6.99 8.10 -8.94%
DY 5.02 0.00 5.26 3.33 4.86 0.00 6.21 -13.25%
P/NAPS 1.51 1.49 1.55 1.35 1.40 1.38 1.25 13.46%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment